About Us
Restoring Brain-Body Homeostasis to Reset Weight, Muscle Mass, and Metabolic Health
Restoring Brain-Body Homeostasis to Reset Weight, Muscle Mass, and Metabolic Health
Restoring Brain-Body Homeostasis to Reset Weight, Muscle Mass, and Metabolic Health
Innovative Therapeutic Strategies Targeting the BDNF-TrkB Pathway for Obesity and Neurodegenerative Diseases. Our molecules activate the couple BDNF-TrkB. BDNF deficiency is known to be the root cause of hyperphagia and metabolic dyregulation. It is also linked to neurodegenerative diseases. BDNF is also necessary for axone and synapse plasticity.
Patented Family of Positive Allosteric Modulators specific of BDNF-TrkB signaling
Restoring Brain-Body Homeostasis to Reset Weight, Muscle Mass, and Metabolic Health
Restoring Brain-Body Homeostasis to Reset Weight, Muscle Mass, and Metabolic Health
15 years of research in prestigious French Universities has led to the discovery of the activity of small, patented molecules, on the BDNF-TrkB pathway. Many preclinical studies demonstrated the affinity and the positive modulation of BDNF in vitro and in vivo.
Mode of Action proven in mutiple preclinical studies, in vitro and in vivo
Restoring Brain-Body Homeostasis to Reset Weight, Muscle Mass, and Metabolic Health
Mode of Action proven in mutiple preclinical studies, in vitro and in vivo
In a model of mice, our leads have shown the reduction of tremors, a key symptom of neurodegeneration.
Our Strategy
Reaching clinical Phase 1 and Partnering
ATEKA Tx intends to perform regulatory pre-clinical studies necessary to test its lead in Pathologic Obesity Syndromes. In parallel, ATEKA Tx will seek grants and partnerships in a large panel of indications and also using its multiple leads and back-up compounds.
CROs
ATEKA is seeking CROs specialised in Obesity and CNS
FOUNDATIONS and BIOPHARMA Partners
ATEKA is open to discussions with Biotech and Pharma players in the CNS Areas, like rare neurodegenerative or psychiatric indications